The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity ...

Get your weekly dose of the top news that matters in our newsletter.

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

With mounting evidence that an infodemic of disinformation about GLP-1 weight loss medicines has become America's second obesity crisis, the National Consumers League (NCL) – a leading non-profit ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

How can policy makers and health care leaders ensure affordable, equitable access to GLP-1 medications while managing their ...

Approaches to dietary interventions among patients with obesity can differ depending on whether they are also being treated ...